Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)

Medicare covers the FDA‑approved Abbott RealTime IDH1 and IDH2 assays to identify susceptible IDH1/IDH2 mutations in adult patients with relapsed or refractory acute myeloid leukemia to guide treatment with ivosidenib (IDH1) or enasidenib (IDH2). Claims must use CPT 81120 (IDH1) or 81121 (IDH2) with 1 unit of service, include the appropriate DEX Z‑Code in the specified claim fields, and report the correct ICD‑10‑CM diagnosis; modified assays require a MolDX Technical Assessment prior to billing.

"Abbott RealTime IDH1 (Abbott Molecular) is FDA‑approved to identify adult AML patients with a susceptible IDH1 mutation to aid selection of treatment with ivosidenib and is covered by Medicare effe..."

Sign up to see full coverage criteria, indications, and limitations.